SCPH SCPharmaceuticals Inc

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024

Management to host conference call and webcast at 4:30 p.m. ET

BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, May 14th, 2024, to discuss the financial results for the first quarter 2024 and provide a business update.

Participants should dial 1-800-717-1738 (domestic) or 1-646-307-1865 (international) with the conference code 89054.

To access the Call Me™ feature, which avoids having to wait for an operator, click .

The live webcast and replay of the conference call can be accessed or under “News & Events” in the Investor Relations section of the Company’s website, .

About scPharmaceuticals

scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that are designed to reduce healthcare costs and improve health outcomes. The Company develops, internally and through strategic partnerships, innovative products and solutions that aim to expand and advance the outpatient care of select acute conditions. The Company’s lead program focuses on the subcutaneous, self-administration of IV-strength treatment in heart failure. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit .

Katherine Miranda

scPharmaceuticals Inc., 781-301-6869

Investors:

PJ Kelleher

LifeSci Advisors, 617-430-7579

 



EN
07/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SCPharmaceuticals Inc

 PRESS RELEASE

scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results an...

scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update Generated 1Q 2024 net FUROSCIX® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents of $58.4 million Company to host investor conference call and webcast today, Tuesday, May 14, at 4:30pm ET BURLINGTON, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potentia...

 PRESS RELEASE

scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConn...

scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference BURLINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference, which will be held at the NASDAQ World Headquarters in New Yor...

 PRESS RELEASE

scPharmaceuticals to Announce First Quarter 2024 Financial Results on ...

scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024 Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, May 14th, 2024, to discuss the financial results ...

 PRESS RELEASE

scPharmaceuticals Announces First Participant Enrolled in Pivotal Phar...

scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful BURLINGTON, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the deli...

 PRESS RELEASE

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Finan...

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update Generated 4Q 2023 net FUROSCIX® revenue of $6.1 million, at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year net FUROSCIX® revenue of $13.6 million, at the upper end of the range provided in January Ended 2023 with cash, cash equivalents and short-term investments of $76 million Company to host investor conference call and webcast today, Wednesday, March 13, at 4:30pm ET BURLINGTON...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch